The future of cancer research points to machine learning!
On 30 January, Stand Up To Cancer, Cancer Convergence executive advisory editor and IAS's Arnie Levine, and Microsoft Research's Jennifer Chayes, introduced an $11M research program that brings together the clinical investigation of the immune system and the computing power of Microsoft's machine learning. Multidisciplinary teams (one of which with the collaboration of Editor-in-Chief David T. Ting) will examine variations in immune system response to an array of cancers to better understand the mechanisms of how immunotherapies work and find new treatments.
About the Editors-in-Chief
Krastan B. Blagoev, PhD
Dr. Blagoev is the Director for the Physics of Living Systems Program in the Division of Physics of the National Science Foundation and an Adjunct Research Scientist at the Department of Biophysics at Johns Hopkins University. Dr. Blagoev's research interests range from cancer progression to clinical trials and organismal aging. Read more
Dr. Blagoev talks about the founding of Cancer Convergence in an interview for the SpringerOpen blog.
David T. Ting, MD
Dr. Ting is Assistant Professor of Medicine at Harvard Medical School and a medical oncologist with focus on gastrointestinal malignancies at the Massachusetts General Hospital (MGH) Cancer Center. Dr. Ting’s laboratory utilizes RNA-sequencing and RNA in situ hybridization technologies for pancreatic cancer theranostics. Read more
Aims and scope
The fundamental and interdependent processes responsible for cancer initiation, tumor progression, and the response to treatment pose challenges that call for multidisciplinary efforts. It is increasingly recognized that no single scientific discipline currently possesses the experimental and conceptual tools needed to address all components of this exceedingly complex and heterogeneous disease process. Cancer Convergence creates a single platform to bring together techniques and synergistic perspectives from different disciplines to facilitate the study and development of strategies for curing cancer. This new journal connects researchers from the physical and mathematical sciences and engineering, who bring quantitative approaches, new questions, and testable hypotheses to the study of cancer, with cancer biologists and research oncologists who represent a long tradition of progress toward understanding the emergence and pathogenesis of the disease. As a platform for collaboration, Cancer Convergence welcomes both qualitative and quantitative approaches that offer new insight into the etiology, mechanisms, diagnosis, or treatment of cancer.
Multifaceted physical, chemical, and biological processes maintain homeostasis in animals, and failure of this intricate process often leads to the development of cancer. Therefore, Cancer Convergence welcomes papers from researchers interested in tissue, organ, and systems maintenance where disruption may be a causal agent of cancer. Overall, the journal aims at understanding the principles that operate during normal function of a complex animal body and their relationship to the cancer processes that govern failure at the cellular, tissue, organ, and systems level. While significant advances have been made in cancer research and treatment, a more interdisciplinary approach is needed to achieve a comprehensive understanding of the disease leading to improved diagnostic and treatment strategies.
Annual Journal Metrics
109 days to first decision for reviewed manuscripts only
109 days to first decision for all manuscripts
158 days from submission to acceptance
13 days from acceptance to publication
16 Altmetric mentions
On the blog
08 January 2018
04 January 2018
Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).
Funding your APC
- ISSN: 2366-6196 (electronic)